ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Lumos Pharma, Inc. (LUMO) stock remained unchanged at $4.34 a share on NASDAQ. The stock opened at $4.33, fluctuating between $4.33 to $4.34 during the session.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Employees | 30 |
Beta | 0.33 |
Sales or Revenue | $2.05M |
5Y Sales Change% | -0.137% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |